title: Revascularization vs. Medical Therapy in Stable Ischemic Heart Disease.
abstract: The keynote COURAGE and BARI-2D trials changed the way the interventional community selects patients for revascularization. What we now consider appropriate, especially for percutaneous coronary intervention, has narrowed significantly in scope compared to previous practice a decade ago. Medical therapy has been shown to be both safe and effective as a primary treatment modality for patients with stable ischemic heart disease on the whole. However, it appears that patients with a heavy ischemic burden may benefit from revascularization, although investigation of this is ongoing. Evidence preliminarily supports this practice with coronary artery bypass grafting, and possibly in specific populations undergoing multivessel intervention with functional assessment of lesion severity during PCI.
authors.affiliation: Christiana Care Health System, Newark, DE.
authors.forename: Sandra
authors.initials: S
authors.lastname: Weiss
authors.affiliation: Christiana Care Health System, Newark, DE. Electronic address: wweintraub@christianacare.org.
authors.forename: William
authors.initials: W
authors.lastname: Weintraub
mesh_terms: D002317:Cardiovascular Agents / Q000009:adverse effects / Q000627:therapeutic use*; D001026:Coronary Artery Bypass / Q000009:adverse effects / Q000401:mortality; D018572:Disease-Free Survival; D006801:Humans; D017202:Myocardial Ischemia / Q000175:diagnosis / Q000401:mortality / Q000628:therapy*; D018579:Patient Selection; D062645:Percutaneous Coronary Intervention / Q000009:adverse effects / Q000401:mortality; D018570:Risk Assessment; D012307:Risk Factors; D013997:Time Factors; D016896:Treatment Outcome
chemical_list: D002317:Cardiovascular Agents
keywords: Optimal medical therapy; Percutaneous coronary intervention; Stable ischemic heart disease